The FDA has approved SimpleScreen CRC, a blood-based screening test developed by Freenome, for average-risk adults aged 45 and older. The test detects cell-free DNA linked to colorectal cancer, and Abbott plans to make it commercially available this fall. The approval is based on results from the PREEMPT CRC study. The test detected 81.1% of […]
FDA Approves Blood Test for Colorectal Cancer Screening Read More »
The phase 2 CHIMERA trial is evaluating whether adding pembrolizumab to standard chemotherapy before and after surgery can improve outcomes for patients with resectable pleural mesothelioma. About 40 adults with previously untreated stage I to IIIa epithelioid or biphasic disease are expected to enroll. Patients will receive three cycles of pembrolizumab combined with platinum-based chemotherapy
CHIMERA Trial Tests Pembrolizumab Around Surgery for Pleural Mesothelioma Read More »
Updated results from the phase 1a FIT-001 trial show that darlifarnib (KO-2806) combined with cabozantinib produced encouraging results in patients with advanced clear cell renal cell carcinoma (ccRCC) who had not previously received cabozantinib. The overall response rate ranged from 33% to 50% across the dose groups, and the median progression-free survival was 13 months.
Darlifarnib Plus Cabozantinib Shows Promising Activity in Advanced Kidney Cancer Read More »
A phase 3 study of cretostimogene grenadenorepvec showed encouraging results in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The treatment produced a complete response in 75.5% of patients at some point during the study. The responses were long-lasting, with a median duration of at least 27.9 months. More
Phase 3 Trial Shows Durable Responses With Cretostimogene in High-Risk Bladder Cancer Read More »
Updated results from the phase 2 J201 study show that safusidenib continues to demonstrate promising long-term activity in patients with treatment-naive grade 2 IDH1-mutant glioma. After a median follow-up of 38.8 months, the drug achieved a confirmed overall response rate of 51.9%, while 79.1% of patients remained free from disease progression at 36 months. The
Safusidenib Shows Durable Activity in IDH1-Mutant Glioma, New Trials Begin Read More »